

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	<del>Not yet assigned</del> 10/712,985
Filing Date	Herewith
First Named Inventor	Franciscus Petrus Nijkamp
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	92750/66

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Jeffrey E. Russell

Date  
Considered

December 28, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not yet assigned 10/712, 985
		Filing Date	Herewith
		First Named Inventor	Franciscus Petrus Nijkamp
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2 of 2	Attorney Docket Number	92750/66	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JN	2	Haddox, J.L., et al., entitled "Bioactivity of Peptide Analogs of the Neutrophil Chemoattractant N-Acetyl-Proline-Glycine-Proline," Investigative Ophthalmology and Visual Science; 1999 Sep; 40(10): 2427-9.	
JN	3	Pfister, R.R., et al., entitled "Injection of Chemoattractants into Normal Cornea A Model of Inflammation After Alkali Injury," Investigative Ophthalmology and Visual Science; 1998 August; 39(9): 1744-50.	
JN	4	Pfister, R.R., et al., entitled "A Neutrophil Chemoattractant is Released from Cellular and Extracellular Components of the Alkali-Degraded Cornea and Blood," Investigative Ophthalmology and Visual Science; 1996 Jan.; 37(1): 230-7.	
JN	5	Blalock, J.E., entitled "Genetic Origins of Protein Shape and Interaction Rules," Nature Medicine; 1995 (1): 876-878.	
JN	6	Pfister, E.A., entitled "Identification and Synthesis of Chemotactic Tripeptides From Alkali-Degraded Whole Cornea A Study of N-Acetyl-Proline-Glycine-Proline and N-Methyl-Proline-Glycine-Proline," Investigative Ophthalmology and Visual Science; 1995 June; 36(7): 1306-16.	
JN	7	Laskin D., et al., entitled "Chemotactic Activity of Collagen-Like Polypeptides for Human Peripheral Blood Neutrophils," Journal of Leukocyte Biology 1986 March; 39(3): 255-66.	

Examiner Signature	Jeffrey E. Russel	Date Considered	December 28, 2004
--------------------	-------------------	-----------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.